Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 DiFusion Receives New Patent
OEM News

DiFusion Receives New Patent

The new US patent 12,178,936 encompasses four methods to manufacture ZFUZE.

DiFusion Technologies announced the issuance of a new US Patent 12,178,936 B2 “Medical Implants and Methods of Manufacture.” The new patent encompasses four methods to manufacture ZFUZE, a proprietary therapeutic, anti-inflammatory, osseoconductive, load-bearing biomaterial for orthopedic implants. 

ZFUZE is the first FDA-cleared advanced biomaterial for spinal implants that is proven to create a highly favorable cellular and immunologic response post-surgery. In a recent 75-patient retrospective study, ZFUZE posted a 93.4% lumbar spinal fusion rate at 6 months while similar competitive studies demonstrate average lumbar fusion rates of 68% at 12 months.

“This new patent firmly protects our ZFUZE FDA Master File for another 17 years. ZFUZE is the only FDA cleared immuno-modulating biomaterial currently available to patients’ surgeons and hospitals,” DiFusion Founder and CEO Derrick Johns. “Building a FDA Master File is a long, arduous and expensive process that larger orthopedic companies are not scientifically equipped to execute.”

Add us as a preferred source on Google

Get the latest Orthopedic Design & Technology news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Orthopedic Design & Technology Newsletters